Potential Buyers Assess Available OTC Assets From Disparate Views
This article was originally published in The Pink Sheet
Executive Summary
As Merck KGAA and Pfizer shop their consumer health businesses, large pharmas J&J, Bayer AG and Sanofi, health and household care marketer Reckitt Benckiser and a smaller firm expanding its OTC focus, Prestige Brands, are among the firms with reasons to consider changing their own consumer health lineups.
You may also be interested in...
Nicorette, Tylenol Ease J&J's Consumer Pain From Slow Oral Care Sales
J&J’s worldwide OTC drug division sales rose 4.4% to $1bn, driven by the Tylenol and Nicorette brands, the firm reports Oct. 17. Those revenues helped offset softness in the firm’s Listerine and other oral care products due to more competition online from start-ups selling straight to consumers.
Church & Dwight Shapes Potential OTC Play On Gummy Format
The firm says sales of L’il Critters children’s and Vitafusion adults’ gummy vitamin lines increased more than 7% in its fiscal 2015 third quarter from the year-ago period as production and distribution began recovering from disruptions that restrained sales in the previous quarter.
J&J Rides Consumer Health ‘Growth Annuity’ As Rx, Device Divisions Slow
Johnson & Johnson’s second-quarter U.S. OTC sales jumped nearly 16% on the return of recalled brands and Worldwide Group Chairman Peterson says J&J expects the consumer business to grow “increasingly” more robust.